The UW Carbone Cancer Center has one of the most active genitourinary oncology programs in the U.S. for treating cancers of the prostate, kidney, bladder, testicles and more. We offer multiple options (surgery, radiation and chemotherapy) combined with the latest research developments to target the cancer as precisely and effectively as possible. Our fellowship-trained, nationally recognized cancer experts are willing to provide opinions regarding management of complex and difficult GU cancers in a timely and efficient manner.

Our oncologists see more than 3,500 patients annually with common as well as rare genitourinary cancers including:

- Bladder Cancer
- Kidney Cancer
- Penile Cancer
- Prostate Cancer
- Urothelial carcinoma of the Renal, Pelvis and Ureter
- Testicular Cancer
- Urethral Cancer

Patients diagnosed with any of these genitourinary cancers are seen by a team of medical, urologic, and radiation oncologists. Each patient is individually evaluated and treatment is tailored to each patient's needs. In addition to treatment, the UW Carbone Cancer Center is committed to improving quality of life and minimizing side effects while undergoing therapy.

Our genitourinary oncologists work collaboratively with regional medical oncologists, keeping patients close to home for therapy whenever possible.
**Urology**

**E. Jason Abel, MD, FACS**  
Residency: University of Utah Hospital, Salt Lake City, UT  
Fellowship: Urologic Oncology, M.D. Anderson Cancer Center, Houston, TX  
Special Interests: Treatment of all genitourinary cancers especially localized and advanced kidney cancer and testis cancer

**Tracy M. Downs, MD, FACS**  
Residency: Brigham & Women's Hospital, Boston, MA  
Fellowship: Urologic Oncology, University of California San Francisco Medical Center, San Francisco, CA  

**Sean P. Hedican, MD**  
Residency: The Johns Hopkins Hospital, Baltimore, MD  
Fellowship: The Johns Hopkins Hospital, Baltimore, MD  
Special Interests: Reconstructive laparoscopy, minimally invasive cancer therapy, robotic surgery, and nerve sparing prostatectomy in the treatment of prostate cancer

**Stephen Y. Nakada, MD, FACS**  
Residency: University of Rochester Medical Center, Rochester, NY  
Fellowship: Washington University Medical Center, St. Louis, MO  
Special Interests: Endoscopic treatment of urinary cancer

**Kyle A. Richards, MD, FACS**  
Residency: Wake Forest University Baptist Medical Center, Winston-Salem, NC  
Fellowship: Urologic Oncology; University of Chicago Medical Center, Chicago, IL  
Special Interests: Robotic bladder, prostate, kidney, and adrenal surgery. Urinary diversions including continent urinary diversion. Complex re-operative surgery and surgery post-radiation

**Medical Oncology**

**Hamid Enamekhoo, MD**  
Residency: Good Samaritan Hospital, Cincinnati, OH  
Fellowship: Hematology and Oncology, Cleveland Clinic, Cleveland, OH  
Special Interests: Focuses on genitourinary malignancies, including clinical trials using immunotherapy and targeted therapies in different stages of kidney, bladder, and prostate cancer

**Christos Kyriakopoulos, MD**  
Residency: Mount Sinai Beth Israel Medical Center, New York, NY  
Fellowship: Jackson Memorial Hospital/Sylvester Comprehensive Cancer Center, Miami, FL and Cleveland Clinic, Cleveland, OH  
Special Interests: Prostate cancer, bladder cancer, kidney cancer, testicular cancer

**Joshua M. Lang, MD**  
Residency: University of Wisconsin Hospital and Clinics, Madison, WI  
Fellowship: Medical Oncology, University of Wisconsin Hospital and Clinics, Madison, WI  
Special Interests: Clinical and translational biomarkers in genitourinary malignancies, molecular targeted therapies, experimental therapeutics and translational clinical trials

**Glenn Liu, MD**  
Residency: University of Wisconsin Hospital and Clinics, Madison, WI  
Fellowship: Oncology, University of Wisconsin Hospital and Clinics, Madison, WI  
Special Interests: Treatment of genitourinary malignancies, conduct of all phases of clinical trials, experimental therapeutics, development of imaging biomarkers

**Douglas G. McNeel, MD, PhD**  
Residency: University of Washington Medical Center, Seattle, WA  
Fellowship: University of Washington Medical Center, Seattle, WA, Fred Hutchinson Cancer Research Center, Seattle, WA  
Special Interests: Prostate cancer immunology, including vaccines for prostate cancer, specifically identifying antigens to target in vaccines, testing the ability of vaccines to eliminate prostate cancer cells and translating these studies to human clinical trials

**Radiation Oncology**

**Gregory M. Cooley, MD**  
Residency: Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI  
Special Interests: Prostate cancer including low and high dose rate brachytherapy, and SpaceOAR® Hydrogel as needed. Accelerated treatments for prostate cancer, including stereotactic body radiation therapy (SBRT)

**Mark A. Ritter, MD, PhD**  
Residency: Hospital of the University of Pennsylvania, Philadelphia, PA  
Special Interests: Radiation therapy for bladder cancer; accelerated treatments for prostate cancer, including stereotactic body radiation therapy (SBRT)